The U.S. President's Emergency Plan for AIDS Relief (PEPFAR)

The U.S. President's Emergency Plan for AIDS Relief (PEPFAR)

Share

This account has been archived since 2/26/2026. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) is the U.S.

Government initiative to help save the lives of those at risk from HIV/AIDS around the world. This historic commitment is the largest by any nation to combat a single disease internationally, and PEPFAR investments also help build health systems to alleviate suffering from other diseases. PEPFAR is driven by a shared responsibility among donor and partner nations and others to make smart investments to save lives.

01/14/2025

women living with HIV are 6x more likely to develop cervical cancer?

Through , PEPFAR is increasing access to:
➡️HPV vaccines to prevent cervical cancer
➡️screenings for early detection
➡️ Treatment of precancerous lesions & referrals

12/27/2024

PEPFAR’s draft 2025 Country/Regional Operational Plan (COP/ROP) guidance has been released for public feedback by January 17.

After the document is finalized following the public feedback period, it will guide PEPFAR’s strategic direction for its pivotal 2025 planning cycle. Brief, actionable feedback to the draft is welcomed

Read 📖 and comment👩‍💻 👇

https://www.state.gov/pepfar-country-operation-planning-2025-guidance-draft-for-public-review

12/19/2024
Global Fund, PEPFAR Announce Coordinated Effort to Reach 2 Million People with Lenacapavir for PrEP to Significantly Reduce Global HIV Infections - United States Department of State 12/17/2024

Today, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) led by GHSD, the The Global Fund, the Children's Investment Fund Foundation (CIFF), and the Bill & Melinda Gates Foundation announced a coordinated effort that will rapidly provide affordable and equitable access to twice-yearly injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP), contingent upon regulatory approval from FDA, relevant national pharmaceutical regulators, and a recommendation from the World Health Organization.

The journal Science named lenacapavir the 2024 Breakthrough of the Year after late-stage trials showed great potential for preventing new HIV infections and accelerating progress toward ending HIV/AIDS as a public health threat by 2030.

HIV prevention options are particularly important for populations who face an increased vulnerability to HIV infection. GHSD supports innovative approaches for HIV prevention and treatment. We stand ready to work with partners around the world to ensure populations most in need have access to interventions approved by FDA and other regulatory bodies.

Global Fund, PEPFAR Announce Coordinated Effort to Reach 2 Million People with Lenacapavir for PrEP to Significantly Reduce Global HIV Infections - United States Department of State GENEVA / WASHINGTON D.C. – The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) and the United States President’s Emergency Plan for AIDS Relief (PEPFAR) have joined forces with the Children’s Investment Fund Foundation (CIFF) and the Bill & Melinda Gates Foundation (BMGF)...

12/10/2024
Want your business to be the top-listed Government Service in Washington D.C.?

Click here to claim your Sponsored Listing.

Location

Address


Washington D.C., DC
20037